AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03224429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sickle Cell Decision Aid
Description: Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
Study NCT00931359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTS-G2 System
Description: Treatment with microwave energy
Study NCT00931359 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DTS System (Sham treatment)
Description: Sham treatment - no energy is delivered
Study NCT02877173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil Liposomes for Injection
Description: 3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
Study NCT02877173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprostadil Injection
Description: Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
Study NCT02434848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years.
Study NCT02434848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fendrix
Description: Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years.
Study NCT04153188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Vbeam® Prima System
Description: 3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.
Study NCT04153188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline HCL 1% Cream
Description: Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
Study NCT04153188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline HCL 1% Cream
Description: Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
Study NCT03801655 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-Kult
Description: 4 capsules/day
Study NCT03801655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules/day
Study NCT02369614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: 1 Hz rTMS
Description: 1 Hz rTMS
Study NCT02369614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: 10 Hz rTMS
Description: 10 Hz rTMS
Study NCT02369614 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator:
Description: Sham rTMS
Study NCT00664833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: The Primary Care Physician (PCP) received the educational intervention
Study NCT00664833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: The Subject received the educational intervention
Study NCT00664833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Both the Primary Care Physician (PCP) and the subject received the educational intervention
Study NCT00664833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Education
Description: No education provided to either the Primary Care Physician (PCP) or the subject.
Study NCT03711578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib,
Description: BID, Orally
Study NCT04338750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Acceptance and Commitment Therapy Intervention for Caregivers
Description: Participants randomized to TACTICs will receive a manualized acceptance and commitment therapy intervention delivered via phone in 6 weekly 1-hour sessions by a trained Bachelor's-level interventionist. Participants in this intervention will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' caregiving experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to anxiety and caregiving challenges. Participants will receive handouts on session topics and a CD with guided mindfulness practices.
Study NCT04338750 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: minimally-Enhanced Usual Care
Description: Participants randomized to mEUC will receive a letter thanking them for participating in the trial along with the Alzheimer's Caregiving guide from the National Institute of Aging of the National Institutes of Health (https://www.nia.nih.gov/health/alzheimers/caregiving), coupled with a listing of the five Alzheimer's Association sponsored support groups closest to their home address.
Study NCT02844556 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: SMILE surgery
Description: SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
Study NCT02844556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FS-LASIK surgery
Description: SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
Study NCT01697735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine;Atorvastatin or Rosuvastatin
Description: Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
Study NCT01697735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin or Rosuvastatin
Description: Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
Study NCT03641664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Centered Treatment
Description: Family Centered Treatment® (FCT) is a promising practice for providing home-based services to families at-risk for their children being removed from home.
Study NCT03641664 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Level II or Level III Out of Home Placement
Description: Residential care for children with emotional, behavioral, and/or mental health in North Carolina who have experienced a level of dysfunction that makes it impossible to function at an age appropriate level in their own homes or in a lower level of care. These services can be provided in a variety of locations from urban to rural, from facility based to community based and from public sector to private sector. This service provides a structured and supervised environment for the acquisition of skills necessary to enable the child to improve level of functioning to achieve and/or to maintain the most realistic level of independent function where earlier treatment gains are somewhat fragile and the child is subject to regression.
Study NCT02097615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate
Description: chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
Study NCT02097615 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: deionized water
Description: application every 24 hours six weeks
Study NCT01487798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 30
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
Study NCT01487798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic human insulin 30
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
Study NCT01487798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
Study NCT01487798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
Study NCT02202759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0264
Description: MLN0264 IV infusion
Study NCT03297112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV
Study NCT03297112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Subharmonic Ultrasound Imaging
Description: Undergo contrast-enhanced subharmonic ultrasound imaging
Study NCT00844961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered cognitive behavior therapy
Description: 10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
Study NCT02494323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
Study NCT01963416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: macro- and micro-nutrient matched control (240 ml)
Study NCT01963416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Study NCT01963416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole orange fruit
Study NCT01963416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Processed whole orange
Study NCT01422343 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous transluminal angioplasty femoro-popliteal
Description: percutaneous transluminal angioplasty femoro-popliteal
Study NCT02461641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NuShield
Description: NuShield is a sterilized dehydrated amnion chorion membrane patch.
Study NCT02461641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affinity
Description: Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
Study NCT02461641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
Study NCT04400201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.
Study NCT04400201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance
Study NCT00512915 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pacemaker implantation
Description: St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
Study NCT02230995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: single dose of metformin given as tablets
Study NCT02230995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin/metformin
Description: Single dose empagliflozin/metformin given as fixed-dose combination tablet
Study NCT02230995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: single dose of empagliflozin given as tablet
Study NCT00218868 — intervention group
Intervention type: PROCEDURE
Intervention: Skin scrape
Description: scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
Study NCT03584477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot InMotion 2.0
Description: Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.
Study NCT03584477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
Study NCT01886066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG)
Description: ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (\~8mm) in the cervical stroma for a total injection volume of 2 mL.
Study NCT00335777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migranal nasal spray at 1 hour
Description: Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
Study NCT00335777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migranal nasal spray at 4 hour
Description: Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
Study NCT02446574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: starting dose 20mg/m2 qw
Study NCT02446574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: dose 25mg/m2 qw
Study NCT02446574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 60Gy/2Gy/30f
Study NCT04775940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perforated collagen membrane
Description: Horizontal Bone Augmentation using Perforated Collagen Membrane
Study NCT04775940 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive collagen membrane
Description: Occlusive collagen membrane
Study NCT02079246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg
Description: once daily, encapsulated tablets, orally
Study NCT02331212 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT02331212 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01209416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acipimox
Description: Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
Study NCT01209416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
Study NCT01209416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo tablets or saline infusion
Study NCT01209416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets or saline infusion
Study NCT02189317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
Study NCT04035460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet
Description: The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
Study NCT04035460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Oxygen
Description: Large-bore nasal prongs through which oxygen is delivered at high flow rates
Study NCT02419001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 - Treatment Sequence AB
Description: Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
Study NCT02419001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 - Treatment Sequence AC
Description: Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
Study NCT02419001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Treatment Sequence AB
Description: Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
Study NCT02419001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Treatment Sequence AC
Description: Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
Study NCT04876378 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04876378 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT03774238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMD analysis
Description: Blood sample and vascular exploration.
Study NCT01209052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756
Description: Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
Study NCT01209052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
Study NCT01385033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-3328
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
Study NCT03209570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care planning using TENA Identifi sensor wear data
Description: All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.
Study NCT03209570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care planning without using TENA Identifi sensor wear data
Description: All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
Study NCT03975985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability exercises (CSE)
Description: CSE are exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (physioball). The exercise involves changes in the position of the body without resistance, aiming to improve strength, endurance, proprioception and coordination.~- TENS: Half of the patients assigned to CSE will also receive TENS (highfrequency TENS 100 Hz; 0.2 ms pulse width), administered via TENS stimulator with two disposable 0.9 mm diameter electrodes placed on the skin over the lumbar erector spinae (3 cm lateral to the L3 and L5 spinous process).